- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SCOPE FLUIDICS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 87,25 | +0,58 % | BioNTech Aktie: Die Wende naht! Golden Cross! | © Foto: 2026 BioNTech SE. Alle Recht vorbehalten.Fast wie in der Serie "Game of Thrones", wo der Winter naht, könnte bei BioNTech die Wende nahen. Nach dem Kursrausch in der Corona-Ära folgte der brutale... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 76,50 | -1,20 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors | IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutical... ► Artikel lesen | |
| IMMUNITYBIO | 8,022 | -6,85 % | ImmunityBio Q4 2026 Earnings Preview | ||
| ARCUTIS BIOTHERAPEUTICS | 23,910 | -3,43 % | Arcutis Biotherapeutics, Inc.: Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis | Phase 1a/1b, first-in-human study to evaluate safety and tolerability for investigational ARQ-234 in healthy volunteers and adults with moderate to severe atopic dermatitisARQ-234 is a potent fusion-protein... ► Artikel lesen | |
| OCUGEN | 1,640 | +3,24 % | Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa | Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and patientsTopline... ► Artikel lesen | |
| CAPRICOR | 22,800 | +2,47 % | Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data | FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review processCompany expects to submit updates to the BLA in February 2026 to support continued FDA review SAN DIEGO,... ► Artikel lesen | |
| REVOLUTION MEDICINES | 87,50 | +1,16 % | Revolution Medicines, Inc.: Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress | On track for readout of RASolute 302, a Phase 3 trial of daraxonrasib in second line metastatic PDAC, in first half of 2026Continues to advance broad late-stage pipeline, with five ongoing Phase 3... ► Artikel lesen | |
| MODERNA | 45,000 | +4,91 % | Moderna: Kombi-Impfung für Grippe und Covid erhält Zulassung | Gute Nachrichten für Moderna: Die EU-Arzneimittelbehörde EMA hat grünes Licht gegeben für den ersten Kombi-Impfstoff gegen Corona und Grippe. Der Wirkstoff solle für Menschen ab 50 Jahren zugelassen... ► Artikel lesen | |
| OSE IMMUNOTHERAPEUTICS | 4,270 | +3,44 % | OSE Immunotherapeutics - Reaffirmed dedication to core assets | OSE Immunotherapeutics has reaffirmed its strategy of streamlining its clinical pipeline following some developments to its partnered assets. For ABBV-230 (OSE-230), partnered with AbbVie, OSE had previously... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 23,370 | -2,71 % | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| SINO BIOPHARM | 0,603 | +0,97 % | SINO BIOPHARM (01177): VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT FOR ROVADICITINIB WITH SANOFI | ||
| TERNS PHARMACEUTICALS | 35,800 | 0,00 % | Terns Pharmaceuticals, Inc.: Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage oncology company, today announced the closing of its... ► Artikel lesen | |
| ARVINAS | 12,980 | -3,06 % | Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials | ||
| JANUX THERAPEUTICS | 13,050 | -2,76 % | Truist cuts Janux Therapeutics stock price target on competition | ||
| VIKING THERAPEUTICS | 27,780 | +1,04 % | Viking Therapeutics: The High-Stakes Weight Loss Contender |
SCOPE FLUIDICS SA gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 28,850 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SCOPE FLUIDICS SA finden Sie auf Wallstreet Online.